<DOC>
	<DOCNO>NCT00697671</DOCNO>
	<brief_summary>The prognosis pediatric patient hematologic malignancy whose disease primarily refractory experience chemotherapy resistant bone marrow relapse extremely poor . When new agent chemotherapeutic regimen unable induce remission patient population , hematopoietic stem cell transplant ( HSCT ) also poor alternative . Thus , high risk group , additional attempt remission induction various combination chemotherapy alone unlikely improve outcome contribute overall toxicity . Alternative therapy need patient chemotherapy resistant disease . Immunotherapy natural killer ( NK ) cell infusion potential decrease toxicity induce hematologic remission . NK cell kill target cell , include leukemia cell , without prior exposure cell . In patient undergo allogeneic HSCT , several study demonstrate powerful effect NK cell leukemia . Furthermore , NK cell infusion patient primary refractory multiple-relapsed leukemia show well tolerate void graft-versus-host disease effect . In high risk group , complete leukemic remission observe several patient NK cell infusion . With current technology available St. Jude , develop procedure purify NK cell adult donor . This protocol ass safety chemotherapy IL-2 administration facilitate transient NK-cell engraftment research participant chemotherapy refractory hematologic malignancy include acute lymphoblastic leukemia , chronic myelogenous leukemia , juvenile myelomonocytic leukemia , myelodysplastic syndrome , non-Hodgkin 's lymphoma . In cohort , also intend explore efficacy NK cell infuse participant chemotherapy refractory disease .</brief_summary>
	<brief_title>Pilot Study Haploidentical Natural Killer Cell Infusions Poor Prognosis Non-AML Hematologic Malignancies</brief_title>
	<detailed_description>This study evaluate persistence , phenotype function donor NK cell well explore efficacy infusion research participant chemotherapy refractory hematologic malignancy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>At least two week since receipt last biological therapy , chemotherapy , radiation therapy . Has suitable adult family member donor available NK cell donation . No current pleural pericardial effusion . HIV negative Adequate clinical standing evidence within multiple renal , hepatic , pulmonary , neurological require test parameter . Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>NK cell infusion</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>Miltenyi Biotec device</keyword>
	<keyword>haploidentical donor</keyword>
</DOC>